Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.44 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28781798 | 0.79 | MEN1 (0.54) | CYP2D6FTOMEN1KMT2APOLB | |
| SCHEMBL3850799 | 0.79 | FTO (0.56) | FTOMEN1KMT2APOLBMAPT | |
| SCHEMBL28781796 | 0.79 | HEXA (0.56) | CYP2D6FTOMEN1KMT2APOLB | |
| SCHEMBL3851928 | 0.78 | MEN1 (0.68) | CYP2D6FTOMEN1KMT2APOLB | |
| SCHEMBL3860282 | 0.78 | KMT2A (0.44) | CYP2D6FTOMEN1KMT2AMAPT | |
| SCHEMBL3851755 | 0.77 | CYP2D6 (0.46) | CYP2D6FTOMEN1KMT2APOLB | |
| SCHEMBL31018801 | 0.77 | KDM4E (0.61) | MEN1KMT2ARECQLRAB9AMAPK1 | |
| SCHEMBL28781804 | 0.77 | HEXA (0.57) | CYP2D6FTOMEN1KMT2APOLB | |
| SCHEMBL3855322 | 0.75 | MEN1 (0.55) | CYP2D6FTOMEN1KMT2APOLB | |
| SCHEMBL2182918 | 0.73 | TSHR (0.66) | CYP2D6MAPTRAB9AMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | claimed |
| EP-1931637-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | claimed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | claimed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | CYP2D6 4809/4885FTO 4015/4885MEN1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.